The first patient has been enrolled in a phase 3 trial of Aldeyra Therapeutics’ allergic conjunctivitis treatment candidate reproxalap, according to a press release.
The randomized, double-masked, crossover vehicle-controlled phase 3 INVIGORATE trial will enroll approximately 120 patients and assess the efficacy and safety of reproxalap ophthalmic solution 0.25% compared with vehicle.
“Initiating enrollment in the INVIGORATE trial moves us closer to our goal of providing allergic conjunctivitis patients with a new treatment option for one of the world’s most common ocular
Uncategorized